The Ebola outbreak in the Democratic Republic of Congo has become the deadliest in that country’s history, public health officials confirmed on Monday. A total of 2,325 people have died since the outbreak was declared on 15 May, surpassing the death toll of the 2018–2020 DRC epidemic. The current outbreak has spread to six of the country’s 26 provinces. The virus involved is the Bundibugyo species, one of the rarest Ebola strains, for which no approved vaccine currently exists, though several candidates are in development including one based on the Oxford-AstraZeneca technology. UN humanitarian chief Tom Fletcher last week warned that “the epidemic is killing someone every 30 minutes.” The Guardian’s reporting notes that the outbreak has reached 4,945 confirmed cases, with 101 new cases in the 24 hours before Monday’s update. Small numbers of cases have appeared in Uganda, Germany, and France, but the primary crisis remains concentrated in Congo’s northeast — a region that has been in continuous armed conflict for three decades.
The received wisdom
The prevailing framing among global health advocates is that this outbreak represents a failure of international solidarity — specifically, a failure to fund the WHO and its emergency response mechanisms adequately, to deliver on vaccine equity commitments made during Covid-19, and to address the structural poverty and conflict that have made DRC a permanent breeding ground for epidemic disease. On this reading, the solution is more resources: more money for the WHO, faster regulatory pathways for new vaccines, better supply chains for personal protective equipment, and sustained diplomatic attention to the eastern DRC conflict that has displaced millions and made contact tracing functionally impossible. The case is sincere and not entirely wrong. The underfunding of global health infrastructure is real, the 2024 WHO reform package remains partly unimplemented, and the disparity between the resources devoted to disease surveillance in high-income countries versus the DRC is enormous. If the world had invested a fraction of the Ukraine reconstruction pledges into Congo’s health infrastructure, the trajectory of this outbreak might look different.
A different read
The international-solidarity framing is partially true and largely insufficient, because it treats the problem as one of resource flows and regulatory pipelines rather than governance and political economy. The DRC has been the site of seventeen Ebola outbreaks since the virus was first identified there fifty years ago. The 2018–2020 epidemic killed 2,280 people. The current outbreak has already passed that threshold in less than three months. The question worth asking is not merely whether the world is giving enough, but why the same geography keeps producing these crises at accelerating frequency and scale — and whether the international health architecture is structurally incapable of solving that problem through the tools it currently deploys.
The answer to the first question is fairly clear. The DRC’s eastern provinces have been in a state of continuous armed conflict since the collapse of the Mobutu regime in 1997. The M23 rebel group, the FDLR, and dozens of smaller armed factions have made sustained public health infrastructure impossible to build or maintain. Contact tracers have been attacked and killed during every major outbreak since 2018. Vaccination campaigns have been disrupted by violence. Health workers operate under constant threat. The WHO knows this. MSF knows this. The DRC government knows this. But the international response framework is built around a model of health emergencies as temporary crises in otherwise functional states — not as permanent features of chronically ungoverned territory. When the model does not fit the reality, the response is to apply the model more vigorously, not to redesign it.
The second question — whether the international health system is incapable of solving this through its current tools — points to the Bundibugyo problem specifically. As the BBC reported, there have been only two prior known outbreaks of the Bundibugyo species, which means the scientific and regulatory infrastructure built up around the more common Zaire strain does not fully apply. The approved Merck vaccine (rVSV-ZEBOV) is effective against Zaire Ebola. It is not approved for Bundibugyo. The MHRA in the UK has just authorised the first human trials of a Bundibugyo vaccine based on the AstraZeneca technology, but trials take time. The world is, in effect, fighting this outbreak without its primary weapon. That is not a resource problem; it is an intelligence failure — a failure to anticipate that a major outbreak of a rare strain was a plausible scenario and to have pre-positioned candidate vaccines in clinical trials before the crisis hit.
There is also a geopolitical dimension. The DRC’s mineral wealth — particularly its coltan, cobalt, and lithium deposits — makes it a site of intense external interest from China, the United States, and regional powers including Rwanda. The incentive structure for major powers in Congo is to manage the conflict, not to resolve it, because resolution might produce a stronger central government with more leverage over resource contracts. Seventeen outbreaks of a disease that, in aggregate, has killed tens of thousands of Congolese people have not fundamentally disrupted those extraction arrangements. That speaks to a political economy that international health governance — designed to mobilise resources, not to alter political incentives — cannot address. Niall Ferguson’s observation about the divergence between humanitarian rhetoric and strategic interest has never had a cleaner illustration.
What to watch
- The pace of the Oxford-AstraZeneca Bundibugyo vaccine trials: if Phase I results come through positive before October, emergency use authorisation is theoretically feasible within months — but that window is tight given the current outbreak trajectory.
- Whether the six-province spread contains itself or breaches the Congo river — a crossing into Kinshasa would transform this from a regional crisis into a potential national one.
- The M23 ceasefire negotiations: any reduction in active fighting in North Kivu and Ituri would meaningfully expand the space for contact tracing and vaccination campaigns.
- Whether the WHO’s 90-day target to “reverse transmission” translates into measurable case-count reductions by mid-September, as the organisation has publicly committed.
— J